Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice

Cancer immunotherapy is a promising way to eliminate tumor cells by using the patient’s own immune system. Selecting the appropriate animal models to develop or validate preclinical immunotherapeutic trials is now an important aspect of many cancer research programs. Here we discuss the advantages a...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Yunsik, Lee, Sanghyuk, Kim, Kapyoul, Kim, Soo-Hyun, Chung, Yeun-Jun, Lee, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6082857/
https://www.ncbi.nlm.nih.gov/pubmed/30089794
http://dx.doi.org/10.1038/s12276-018-0115-0
Descripción
Sumario:Cancer immunotherapy is a promising way to eliminate tumor cells by using the patient’s own immune system. Selecting the appropriate animal models to develop or validate preclinical immunotherapeutic trials is now an important aspect of many cancer research programs. Here we discuss the advantages and limitations of using genetically engineered immunodeficient mouse models, patient-derived xenografts (PDXs), and humanized mouse models for developing and testing immunotherapeutic strategies.

Ejemplares similares